Literature DB >> 22396243

Lead time TTO: leading to better health state valuations?

Arthur E Attema1, Matthijs M Versteegh, Mark Oppe, Werner B F Brouwer, Elly A Stolk.   

Abstract

Preference elicitation tasks for better than dead (BTD) and worse than dead (WTD) health states vary in the conventional time trade-off (TTO) procedure, casting doubt on uniformity of scale. 'Lead time TTO' (LT-TTO) was recently introduced to overcome the problem. We tested different specifications of LT-TTO in comparison with TTO in a within-subject design. We elicited preferences for six health states and employed an intertemporal ranking task as a benchmark to test the validity of the two methods. We also tested constant proportional trade-offs (CPTO), while correcting for discounting, and the effect of extending the lead time if a health state is considered substantially WTD. LT-TTO produced lower values for BTD states and higher values for WTD states. The validity of CPTO varied across tasks, but it was higher for LT-TTO than for TTO. Results indicate that the ratio of lead time to disease time has a greater impact on results than the total duration of the time frame. The intertemporal ranking task could not discriminate between TTO and LT-TTO.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22396243     DOI: 10.1002/hec.2804

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  22 in total

1.  Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.

Authors:  Fatima Al Sayah; Nick Bansback; Stirling Bryan; Arto Ohinmaa; Lise Poissant; Eleanor Pullenayegum; Feng Xie; Jeffrey A Johnson
Journal:  Qual Life Res       Date:  2015-12-10       Impact factor: 4.147

Review 2.  Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research.

Authors:  Patricia Cubi-Molla; Koonal Shah; Kristina Burström
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

3.  Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study.

Authors:  Fatima Al Sayah; Jeffrey A Johnson; Arto Ohinmaa; Feng Xie; Nick Bansback
Journal:  Qual Life Res       Date:  2017-01-25       Impact factor: 4.147

4.  Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best-worst scaling?

Authors:  Feng Xie; Eleanor Pullenayegum; Kathryn Gaebel; Mark Oppe; Paul F M Krabbe
Journal:  Eur J Health Econ       Date:  2013-04-04

5.  The impact of a belief in life after death on health-state preferences: True difference or artifact?

Authors:  Michał Jakubczyk; Dominik Golicki; Maciej Niewada
Journal:  Qual Life Res       Date:  2016-07-21       Impact factor: 4.147

6.  How different are composite and traditional TTO valuations of severe EQ-5D-5L states?

Authors:  Feng Xie; Eleanor Pullenayegum; Kathy Gaebel; Nick Bansback; Stirling Bryan; Arto Ohinmaa; Lise Poissant; Jeffrey A Johnson
Journal:  Qual Life Res       Date:  2016-02-13       Impact factor: 4.147

7.  Time to tweak the TTO: results from a comparison of alternative specifications of the TTO.

Authors:  Matthijs M Versteegh; Arthur E Attema; Mark Oppe; Nancy J Devlin; Elly A Stolk
Journal:  Eur J Health Econ       Date:  2013-07

8.  How dead is dead? Qualitative findings from participants of combined traditional and lead-time time trade-off valuations.

Authors:  Fatima Al Sayah; Ana Mladenovic; Kathryn Gaebel; Feng Xie; Jeffrey A Johnson
Journal:  Qual Life Res       Date:  2015-07-28       Impact factor: 4.147

9.  Demographic differences in health preferences in the United States.

Authors:  Benjamin M Craig; Bryce B Reeve; David Cella; Ron D Hays; Alan S Pickard; Dennis A Revicki
Journal:  Med Care       Date:  2014-04       Impact factor: 2.983

10.  The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework.

Authors:  Nan Luo; Minghui Li; Elly A Stolk; Nancy J Devlin
Journal:  Eur J Health Econ       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.